| Literature DB >> 31810584 |
Irene Rosas1, Carmen Martínez2, Jordi Clarimón3, Alberto Lleó3, Ignacio Illán-Gala3, Oriol Dols-Icardo3, Barbara Borroni4, Maria Rosário Almeida5, Julie van der Zee6, Christine Van Broeckhoven6, Amalia C Bruni7, Maria Anfossi7, Livia Bernardi7, Raffaele Maletta7, María Serpente8, Daniela Galimberti8, Elio Scarpini8, Giacomina Rossi9, Paola Caroppo9, Luisa Benussi10, Roberta Ghidoni10, Giuliano Binetti10, Benedetta Nacmias11, Sandro Sorbi11, Irene Piaceri11, Silvia Bagnoli11, Anna Antonell12, Raquel Sánchez-Valle12, Beatriz De la Casa-Fages13, Francisco Grandas13, Mónica Diez-Fairen14, Pau Pastor14, Raffaele Ferrari15, Victoria Álvarez16, Manuel Menéndez-González17.
Abstract
We analyzed the frequency of intermediate alleles (IAs) in the ATXN1, ATXN2, and HTT genes in several neurodegenerative diseases. The study included 1126 patients with Alzheimer's disease (AD), 440 patients with frontotemporal dementia (FTD), and 610 patients with Parkinson's disease. In all cohorts, we genotyped ATXN1 and ATXN2 CAG repeats. In addition, in the FTD cohort, we determined the number of HTT CAG repeats. The frequency of HTT IAs was higher in patients with FTD (6.9%) versus controls (2.9%) and in the C9orf72 expansion noncarriers (7.2%) versus controls (2.9%), although the difference was nonsignificant after correction for multiple testing. Compared with controls, progressive nonfluent aphasia (PNFA) groups showed a significantly higher frequency of HTT IAs (13.6% vs. 2.9% controls). For the ATXN2 gene, we observed an increase in IA frequency in AD cases (AD 4.1% vs. controls 1.8%) and in the behavioral FTD group (4.8% vs. 1.8%). For the ATXN1 gene, we found a significant increase of IAs in patients with PNFA (18.6%) versus controls (6.7%). In conclusion, our work suggests that the HTT and ATXN1 IAS may contribute to PNFA pathogenesis and point to a link between ATXN2 IAS and AD.Entities:
Keywords: CAG repeats; Intermediate alleles; Neurodegeneration; Tauopathies
Year: 2019 PMID: 31810584 DOI: 10.1016/j.neurobiolaging.2019.10.017
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673